Propel testing excellence with Mayo Clinic quality
Mayo Clinic Laboratories is a one-stop laboratory solution, offering commercial laboratories a vast testing menu, unparalleled customer service, and optimized processes. We work collaboratively with partners to assess their needs, providing the testing they need to expand into new areas and meet their business goals.
As the reference lab for Mayo Clinic, we’ve developed robust logistics and testing protocols applied uniformly for all specimens received, no matter their geographic origin. Whether you send us one test order or thousands, each sample receives the same treatment and level of care, ensuring superior results that help our partners better serve their clients.
“Our clients want personal experiences. They want someone to answer the phone. They want someone to provide answers when they're looking for results of a sample sent a couple days ago. and we deliver those answers.”
Angie Reese-Davis, director of operations, logistics, and specimen services, Mayo Clinic Laboratories
Our difference
News and updates
The latest
In this episode of the “Leveraging the Laboratory” podcast, Jane Hermansen, outreach manager at Mayo Clinic Laboratories, welcomes Chelsea Conn, Mayo Clinic Laboratories’ director of regulatory affairs. Together, they break down the latest regulatory changes and share actionable strategies to help outreach programs stay informed and prepared.
This week on "Answers From the Lab," William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, joins "Answers From the Lab" for his weekly leadership update with host Bobbi Pritt, M.D. In this episode, Dr. Pritt and Dr. Morice discuss how monkeypox can be transmitted, the possibilities of a future Emergency Use Authorization (EUA), and access to testing.
This “phlebotomy webinar” will walk learners through the quality improvement methodology and describe PDSA cycle interventions that were implemented in this unit which successfully reduced the amount of canceled labs due to specimen integrity.
Tim Plummer is an operations administrator at Mayo Clinic Laboratories supporting the Division of Anatomic Pathology. He supports his team members by providing them with tools and resources to innovate and succeed. He has worked at Mayo Clinic for over 36 years and is driven by the determination to help people solve problems, help others be happy and successful, and be a part of solutions.
John Lieske, M.D., describes Mayo Clinic Laboratories' new test for primary membranous nephropathy. PMND1 is a diagnostic cascade that provides a cost-effective approach to detecting antigens known to cause membranous nephropathy — a condition that can lead to kidney failure.
This week's research roundup features: Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults.
Darci Block, Ph.D., of the Department of Laboratory Medicine and Pathology at Mayo Clinic, authored an article in the American Association for Clinical Chemistry’s (AACC) Clinical Laboratory News highlighting hurdles in body fluid testing.
Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology in the Department of Laboratory Medicine and Pathology at Mayo Clinic and director of the Clinical Parasitology Laboratory, provides her perspective on parasites in the latest edition of National Geographic magazine.
Topic highlights include: Mayo Clinic doctors weigh in on all things back-to-school, Trial seeks to develop first Lyme disease vaccine in 2 decades, New York health department says hundreds of people may be infected with polio virus.
In this episode, Dr. Pritt and Dr. Morice discuss new developments in monkeypox testing, updates on the federal response, and lessons learned from managing other viruses.
In a recent study, Mayo Clinic researchers developed the first cellular DNA barcoding with a machine-learning approach to reveal previously unknown metastatic behavior of tumor cells. Researchers barcoded the DNA of millions of human ovarian cancer cells and transplanted them in mice, where rare tumor initiating cells and their progenies could be tracked within the primary tumor as well as in every other organ they were spreading into. The entire community of cells generated by a single barcoded cell had identical barcodes. This enabled the tracking of a large number of benign and metastatic clones by sequencing DNA barcodes in tumors and various organs, including blood and ascites. Using the cellular DNA barcoding approach and a newly developed data analysis system, researchers could track clonal growth dynamics in various metastatic sites and trace it back to its ancestral tumor-initiating cell. They used artificial intelligence to tackle the complex data to identify if the clonal metastatic spread is happening peritoneally or through blood routes.
Rong He, M.D., describes how Mayo Clinic Laboratories’ NPM1Q assay detects all known forms of a genetic mutation found in about 30% of people with acute myeloid leukemia, or AML. Identifying the NPM1 mutation is critical for clinical decision-making.
This week's research roundup features: Type 1, type 2 myocardial infarction and non-ischemic myocardial injury-opinion from the front lines